Your browser doesn't support javascript.
loading
Antiretroviral treatment failure predicts mortality in rural Tanzania.
Pettersen, Pernille S; Brox, Ida K; Naman, Ezra; Bruun, Johan N; Dyrhol-Riise, Anne M; Trøseid, Marius; Johannessen, Asgeir.
Afiliação
  • Pettersen PS; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Brox IK; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Naman E; HIV Care and Treatment Center, Haydom Lutheran Hospital, Mbulu, Tanzania.
  • Bruun JN; University Hospital of Northern Norway, Tromsø, Norway.
  • Dyrhol-Riise AM; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.
  • Trøseid M; Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.
  • Johannessen A; Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway Vestre Viken HF, Drammen Hospital, Drammen, Norway johannessen.asgeir@gmail.com.
Int J STD AIDS ; 26(9): 633-9, 2015 Aug.
Article em En | MEDLINE | ID: mdl-25122578
Virological monitoring of HIV-infected patients on antiretroviral treatment (ART) is rarely available in resource-limited settings and many patients experience unrecognized virological failure. We studied the long-term consequences of virological failure in rural Tanzania. Previously, virological efficacy was measured in a cohort treated with ART. In the present study, patients with virological failure (VF; HIV-RNA >400 copies/ml) were followed up and compared to those with virological response (VR; HIV-RNA <400 copies/ml) with regard to mortality, CD4 change and subsequent virological outcome. Fifty-six patients with VF had a median CD4 count of 358 cells/µl (interquartile range [IQR] 223-635) and a median HIV-RNA of 13,573 copies/ml (IQR 2326-129,736). Median CD4 count for those with VR was 499 cells/µl (IQR 290-636). During a median follow-up time of 39 months (IQR 18-42), 8 of 56 patients (14.3%) with VF died, compared to 1 of 63 patients (1.6%) with VR (p = 0.009). All registered deaths were HIV-related. Of 55 patients with subsequent HIV-RNA measurements, only 12 of 30 (40%) patients with VF achieved virological suppression, compared to 20 of 25 (80%) patients with VR (p = 0.003). Virological failure predicted death and subsequent virological failure in patients on ART in a resource-limited setting.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV / Terapia Antirretroviral de Alta Atividade Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV / Terapia Antirretroviral de Alta Atividade Idioma: En Ano de publicação: 2015 Tipo de documento: Article